Table of Contents Author Guidelines Submit a Manuscript

A corrigendum for this article has been published. To view the corrigendum, please click here.

International Journal of Endocrinology
Volume 2017, Article ID 5469409, 5 pages
Review Article

Inositol and In Vitro Fertilization with Embryo Transfer

Division of Obstetrics and Gynecology Oncology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Correspondence should be addressed to P. G. Artini; ti.ipinu.dem@initra.oloap

Received 7 July 2016; Accepted 13 October 2016; Published 28 February 2017

Academic Editor: Vittorio Unfer

Copyright © 2017 G. Simi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recently, studies on inositol supplementation during in vitro fertilization program (IVF) have gained particular importance due to the effect of this molecule on reducing insulin resistance improving ovarian function, oocyte quality, and embryo and pregnancy rates and reducing gonadotropin amount during stimulation. Inositol and its isoforms, especially myoinositol (MYO), are often used as prestimulation therapy in infertile patients undergoing IVF cycle. Inositol supplementation started three months before ovarian stimulation, resulting in significant improvements in hormonal responses, reducing the amount of FSH necessary for optimal follicle development and serum levels of 17beta-estradiol measured the day of hCG injection. As shown by growing number of trials, MYO supplementation improves oocyte quality by reducing the number of degenerated and immature oocytes, in this way increasing the quality of embryos produced. Inositol can also improve the quality of sperm parameters in those patients affected by oligoasthenoteratozoospermia.